Letters to the Editor

Five-year results of short-course brentuximab vedotin combined with chemotherapy and radiation in early stage, unfavorable Hodgkin lymphoma

Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Wilmot Cancer Institute, University of Rochester, Rochester
Stanford Cancer Institute, Stanford University, Stanford, CA
City of Hope, Duarte, CA
Stanford Cancer Institute, Stanford University, Stanford, CA
Genentech, South San Francisco, CA
Memorial Sloan Kettering Cancer Center, New York
Stanford Cancer Institute, Stanford University, Stanford, CA
Memorial Sloan Kettering Cancer Center, New York
City of Hope, Duarte, CA
Wilmot Cancer Institute, University of Rochester, Rochester
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Stanford Cancer Institute, Stanford University, Stanford, CA
Memorial Sloan Kettering Cancer Center, New York
City of Hope, Duarte, CA
Memorial Sloan Kettering Cancer Center, New York
Rutgers Cancer Institute, New Brunswick, New Jersey
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Siteman Cancer Center, Washington University in Saint Louis, St. Louis, MO
Memorial Sloan Kettering Cancer Center, New York
University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Haematologica Early view Oct 1, 2026 https://doi.org/10.3324/haematol.2026.301587